Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Open Access
- 1 January 2018
- journal article
- research article
- Published by Elsevier BV in World Allergy Organization Journal
- Vol. 11 (1), 33
- https://doi.org/10.1186/s40413-018-0214-3
Abstract
No abstract availableKeywords
Funding Information
- Novartis Farma SpA
This publication has 42 references indexed in Scilit:
- Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)BMJ Open, 2016
- The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthmaRespiratory Medicine, 2013
- Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New ApproachesJournal of Asthma, 2012
- Omalizumab in patients with severe asthma: the XCLUSIVE studyThe Clinical Respiratory Journal, 2011
- Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomesPatient Related Outcome Measures, 2011
- Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life dataRespiratory Medicine, 2010
- “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST studyRespiratory Medicine, 2009
- The Brief Illness Perception QuestionnaireJournal of Psychosomatic Research, 2006
- Seasonal and perennial allergic rhinitis: is this classification adherent to real life?Allergy, 2005
- The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthmaEuropean Respiratory Journal, 2003